First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial
about
Bisphosphonates in multiple myeloma: a network meta-analysisCurrent Trends of Renal Impairment in Multiple MyelomaMultiple myeloma in the very elderly patient: challenges and solutionsHuman isoprenoid synthase enzymes as therapeutic targetsDangER: protein ovERload. Targeting protein degradation to treat myelomaCurrent and emerging treatment options for patients with relapsed myelomaThe promise of γδ T cells and the γδ T cell receptor for cancer immunotherapyInternational Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantationDiagnosis and treatment of bone disease in multiple myeloma: spotlight on spinal involvementγδ T cells for cancer immunotherapy: A systematic review of clinical trialsOsteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche.Discovery of Novel Allosteric Non-Bisphosphonate Inhibitors of Farnesyl Pyrophosphate Synthase by Integrated Lead FindingDiagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation OncologyBone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myelomaRecognizing and treating secondary osteoporosisOsteolytica: An automated image analysis software package that rapidly measures cancer-induced osteolytic lesions in in vivo models with greater reproducibility compared to other commonly used methodsThe CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myelomaCommon variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma riskCommon variation at 3p22.1 and 7p15.3 influences multiple myeloma riskStatins Are Associated With Reduced Mortality in Multiple Myeloma.Anti-Tumor Activity and Immunotherapeutic Potential of a Bisphosphonate Prodrug.Bone disease in multiple myeloma: pathophysiology and management.A Novel Prothrombotic Pathway in Systemic Sclerosis Patients: Possible Role of Bisphosphonate-Activated γδ T Cells.The sialyltransferase ST3GAL6 influences homing and survival in multiple myelomaMapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival.Circulating tumor cell count during zoledronic acid treatment in men with metastatic prostate cancer: a pilot studyMaintaining bone health in patients with multiple myeloma: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board.Zoledronate attenuates angiogenic effects of angiotensin II-stimulated endothelial progenitor cells via RhoA and MAPK signaling.Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis.Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocationsEffects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trialCyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation.Prediction of drug indications based on chemical interactions and chemical similarities.Approach to the treatment of multiple myeloma: a clash of philosophies.Changes in renal function after different tandem hematopoietic stem-cell transplantation approaches in patients with multiple myeloma.Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management.Comparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma.The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future.Targeting bone as a therapy for myeloma.Neuroblastoma killing properties of Vδ2 and Vδ2-negative γδT cells following expansion by artificial antigen-presenting cells.
P2860
Q24197839-9079261A-B1A0-49C4-9BC8-8A74DE1078C9Q26740444-CC49CC2F-AA3E-4356-A56C-D802E8DF908AQ26752991-03DF07E1-791B-4E86-A8A0-E6A39F2C2762Q26822639-4D9D03E7-A4B8-4F05-A26E-1880AE01DD03Q26825417-855254FC-63B4-4EBC-B236-8C630FD83D4DQ26830878-022FB7E0-F761-4F92-BA52-58FA643F6D4DQ26859775-C1815A2C-83B5-4925-B534-F085757728A3Q27002668-495F991F-3CC6-4A34-8A12-4566D048125AQ27011865-ABB93120-BE51-471E-B938-A10079B0891CQ27021705-8D3F0104-6F41-4D14-AD9B-FC913A16781AQ27316833-DE30571A-E2C8-4CBD-BCF1-1A123A354A8EQ27702178-0BB956D4-7CF0-4277-A874-7D7EDFED9435Q28076646-834EB69E-A4B2-4A0A-A948-24953DF2984DQ28081996-81FED22C-A255-4AE8-BD00-A4D3594FA3F9Q28270738-275C80C0-CD25-45DA-AA0D-D2EAE26964DFQ28364664-81E08685-50C0-4118-B6FB-76B652DDFE16Q28391289-D3C2A8FC-9E55-404C-90E7-90DA87BD7AA6Q28943335-1DA51D43-98C2-4F69-819B-3277745036BCQ28943395-8E184972-9946-4337-9955-2EB10BB377AEQ33816591-4CE473FC-BC33-4A1D-B60E-4CFD5B5CA0C1Q33920919-F5A3C35A-055E-4E58-B093-FB0B57B2549EQ34045789-2B36C4E4-E821-41FA-A350-1FFAC40A9976Q34148693-5CE50A23-797B-43BE-AEB7-7C6D483E9E99Q34170367-E019E38C-712C-401B-9F64-3B2F49CFE767Q34223730-DC1F6516-5774-494C-8A33-90DC24C721AAQ34294905-979E824D-B386-4BFE-8FE4-CE94929172AFQ34307388-3764560B-AC3A-4199-98F0-008C23973764Q34447189-2F343F9E-BC43-478D-91E1-7A7BE8E4D7A5Q34583705-B3D90671-0B12-4C43-BB4E-5BE110974B8BQ35081172-2044CB1F-1C14-4A1D-89E5-789B27D3DA2FQ35141814-D8712305-8C2C-400B-A36E-2D3C6559F495Q35153760-8EC57B41-F910-4C6E-8783-5C0B5C29CA81Q35187910-4358553F-F391-40A6-B928-9445DD6A7FC5Q35230189-4813B833-5082-405C-B596-F6D7C2BEF0EDQ35333741-1B8384D7-6B5A-496A-9015-FA083F1225C9Q35422468-1E831332-66CF-4CF7-96AF-89FA76063F3CQ35441390-98779CB8-F655-4358-AA42-D8DD3FBBDC11Q35584866-3F41ED7C-10FE-4FD3-A523-0D1C138013CDQ35603128-71DB3657-7FB7-4606-8E41-F715F5EC6170Q35654544-5A809EAF-93B5-4BAA-B9AD-3FC370F185D5
P2860
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
First-line treatment with zole ...... a randomised controlled trial
@ast
First-line treatment with zole ...... a randomised controlled trial
@en
First-line treatment with zole ...... a randomised controlled trial
@en-gb
type
label
First-line treatment with zole ...... a randomised controlled trial
@ast
First-line treatment with zole ...... a randomised controlled trial
@en
First-line treatment with zole ...... a randomised controlled trial
@en-gb
prefLabel
First-line treatment with zole ...... a randomised controlled trial
@ast
First-line treatment with zole ...... a randomised controlled trial
@en
First-line treatment with zole ...... a randomised controlled trial
@en-gb
P2093
P2860
P1433
P1476
First-line treatment with zole ...... a randomised controlled trial
@en
P2093
A John Ashcroft
Alex J Szubert
Claudius Rudin
Faith E Davies
Fiona Ross
Gordon Cook
Graham H Jackson
Huw Roddie
J Anthony Child
Jennifer Byrne
P2860
P304
P356
10.1016/S0140-6736(10)62051-X
P407
P577
2010-12-03T00:00:00Z